This suggested that the synergistic interaction between IL-3-activated macrophages and GCV-mediated anti-HSV-sr39tk cell cytotoxicity promoted the development of a Th1 immune response and subsequently contributed to the enhanced anti-tumor activity observed on combining IL-3 and HSV-sr39tk/GCV therapies. Here, IL3 is linked to neoplasm.